Gene · 2823
Papers1,924
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 1,924
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| N6‑methyladenosine methyltransferase METTL14 is associated with macrophage polarization in rheumatoid arthritis. | Exp Ther Med | 2024 | 39113907 | PubTator, text mining | PubMed |
| Predicting prognosis and drug sensitivity in bladder cancer: an insight into Pan-programmed cell death patterns regulated by M6A modifications. | Sci Rep | 2024 | 39112614 | PubTator, text mining | PubMed |
| piR-27222 mediates PM2.5-induced lung cancer by resisting cell PANoptosis through the WTAP/m6A axis. | Environ Int | 2024 | 39106633 | PubTator, text mining | PubMed |
| The Roles of RNA N6-methyladenosine Modifications in Systemic Lupus Erythematosus. | Cell Biochem Biophys | 2024 | 39095568 | PubTator, text mining | PubMed |
| Targeted inhibition of m6A demethylase FTO by FB23 attenuates allergic inflammation in the airway epithelium. | FASEB J | 2024 | 39093041 | PubTator, text mining | PubMed |
| FTO/m6A/GPNMB axis: a novel promising target for hepatocellular carcinoma (HCC) treatment? | Gut | 2024 | 39089861 | PubTator, text mining | PubMed |
| N6-methyladenosine triggers renal fibrosis via enhancing translation and stability of ZEB2 mRNA. | J Biol Chem | 2024 | 39059495 | PubTator, text mining | PubMed |
| RNA modification Regulators' Co-Expression Score (RMRCoeS) predicts biochemical recurrence and therapy response in prostate cancer: A multi-omics and experimental validation study. | Int Immunopharmacol | 2024 | 39053228 | PubTator, text mining | PubMed |
| The role of N6-methyladenosine RNA methylation in the crosstalk of circadian clock and neuroinflammation in rodent suprachiasmatic nuclei. | Eur J Neurosci | 2024 | 39007275 | PubTator, text mining | PubMed |
N6-methyladenosine demethylase ALKBH5 homologous protein protects against cerebral I/R injury though suppressing SNHG3-mediated neural PANoptosis: Involvement of m6A-related macromolecules in the diseases of nervous system. | Int J Biol Macromol | 2024 | 38996894 | PubTator, text mining | PubMed |
| Branch Chain Amino Acid Metabolism Promotes Brain Metastasis of NSCLC through EMT Occurrence by Regulating ALKBH5 activity. | Int J Biol Sci | 2024 | 38993559 | PubTator, text mining | PubMed |
| A genetic variant in the TAPBP gene enhances cervical cancer susceptibility by increasing m6A modification. | Arch Toxicol | 2024 | 38992170 | PubTator, text mining | PubMed |
| Deficiency of m 6 A RNA methylation promotes ZBP1-mediated cell death. | bioRxiv | 2024 | 38979320 | PubTator, text mining | PubMed |
| M6A modification and T cells in adipose tissue inflammation. | Cell Biochem Funct | 2024 | 38978329 | PubTator, text mining | PubMed |
| Roles of m6A modification in regulating PPER pathway in cadmium-induced pancreatic β cell death. | Ecotoxicol Environ Saf | 2024 | 38968870 | PubTator, text mining | PubMed |
| RNA demethylase FTO participates in malignant progression of gastric cancer by regulating SP1-AURKB-ATM pathway. | Commun Biol | 2024 | 38956367 | PubTator, text mining | PubMed |
| Prognostic signature and immune efficacy of m1A-, m5C-, m6A-, m7G-, and DNA methylation-related regulators in hepatocellular carcinoma. | J Cancer | 2024 | 38947378 | PubTator, text mining | PubMed |
| M6A demethylase FTO-stabilized exosomal circBRCA1 alleviates oxidative stress-induced granulosa cell damage via the miR-642a-5p/FOXO1 axis. | J Nanobiotechnology | 2024 | 38918838 | PubTator, text mining | PubMed |
| Editorial: Insights in synaptic neuroscience 2022. | Front Synaptic Neurosci | 2024 | 38915459 | PubTator, text mining | PubMed |
| Exploring the role of m 6 A writer RBM15 in cancer: a systematic review. | Front Oncol | 2024 | 38915367 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2823/papers?page=11